Trovagene Investor Relations Trovagene Investor Relations Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine Methodology to assess changes in leukemic cells, genomic alterations and pTCTP status for Phase 1b/2 Clinical Trial of PCM-075. Update on clinical trial recruitment. Tue, 17 Apr 2018 11:00:00 -0700 Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML) Combination of PCM-075, a highly-selective Polo-like Kinase 1 (PLK1) inhibitor, and Quizartinib resulted in 97% tumor growth inhibition and regression in FLT3 AML model Mon, 16 Apr 2018 06:00:00 -0700 Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018 Thu, 12 Apr 2018 13:11:00 -0700 Trovagene to Present at the 26th Annual Wall Street Investor Conference Tue, 20 Mar 2018 05:00:00 -0700 Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial Mon, 05 Mar 2018 05:00:00 -0800